Seres Therapeutics (MCRB) Announces SER-287 Phase 1b Microbiome Analyses that Provide Mechanistic Support for Clinical Efficacy in Ulcerative Colitis
Tweet Send to a Friend
Seres Therapeutics, Inc., (NASDAQ: MCRB) today announced initial microbiome results from its Phase 1b study of SER-287, a microbiome therapeutic ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
